139 related articles for article (PubMed ID: 25015667)
1. Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virological failure.
Rozera G; Abbate I; Giombini E; Castagna A; De Luca A; Ceccherini-Silberstein F; Cozzi Lepri A; Cassola G; Torti C; d'Arminio Monforte A; Ippolito G; Capobianchi MR;
J Antimicrob Chemother; 2014 Nov; 69(11):3085-94. PubMed ID: 25015667
[TBL] [Abstract][Full Text] [Related]
2. Analysis of co-receptor usage of circulating viral and proviral HIV genome quasispecies by ultra-deep pyrosequencing in patients who are candidates for CCR5 antagonist treatment.
Abbate I; Rozera G; Tommasi C; Bruselles A; Bartolini B; Chillemi G; Nicastri E; Narciso P; Ippolito G; Capobianchi MR
Clin Microbiol Infect; 2011 May; 17(5):725-31. PubMed ID: 20731681
[TBL] [Abstract][Full Text] [Related]
3. Concordance between HIV-1 genotypic coreceptor tropism predictions based on plasma RNA and proviral DNA.
Verhofstede C; Brudney D; Reynaerts J; Vaira D; Fransen K; De Bel A; Seguin-Devaux C; De Wit S; Vandekerckhove L; Geretti AM
HIV Med; 2011 Oct; 12(9):544-52. PubMed ID: 21518222
[TBL] [Abstract][Full Text] [Related]
4. Dynamics of HIV tropism under suppressive antiretroviral therapy: implications for tropism testing in subjects with undetectable viraemia.
Seclén E; Del Mar González M; De Mendoza C; Soriano V; Poveda E
J Antimicrob Chemother; 2010 Jul; 65(7):1493-6. PubMed ID: 20488982
[TBL] [Abstract][Full Text] [Related]
5. Deep-Sequencing Analysis of the Dynamics of HIV-1 Quasiespecies in Naive Patients during a Short Exposure to Maraviroc.
Cascajero A; Rastrojo A; Díez-Fuertes F; Hernández-Novoa B; Aguado B; Moreno S; Alcami J; Pérez-Olmeda M
J Virol; 2018 Jun; 92(11):. PubMed ID: 29563289
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic Immune Recovery and Reduction of CXCR4-Tropic HIV-1.
Bader J; Däumer M; Schöni-Affolter F; Böni J; Gorgievski-Hrisoho M; Martinetti G; Thielen A; Klimkait T;
Clin Infect Dis; 2017 Feb; 64(3):295-300. PubMed ID: 27838645
[TBL] [Abstract][Full Text] [Related]
7. High concordance of genotypic coreceptor prediction in plasma-viral RNA and proviral DNA of HIV-1 subtype C: implications for use of whole blood DNA in resource-limited settings.
Gupta S; Neogi U; Srinivasa H; Shet A
J Antimicrob Chemother; 2013 Sep; 68(9):2003-6. PubMed ID: 23633683
[TBL] [Abstract][Full Text] [Related]
8. Evolution of proviral DNA HIV-1 tropism under selective pressure of maraviroc-based therapy.
Baroncelli S; Galluzzo CM; Weimer LE; Pirillo MF; Volpe A; Mercuri A; Cavalli A; Fragola V; Monno L; Degli Antoni A; Ladisa N; Francisci D; Bucciardini R; Floridia M
J Antimicrob Chemother; 2012 Jun; 67(6):1479-85. PubMed ID: 22361986
[TBL] [Abstract][Full Text] [Related]
9. Co-receptor switch during HAART is independent of virological success.
Saracino A; Monno L; Cibelli DC; Punzi G; Brindicci G; Ladisa N; Tartaglia A; Lagioia A; Angarano G
J Med Virol; 2009 Dec; 81(12):2036-44. PubMed ID: 19856465
[TBL] [Abstract][Full Text] [Related]
10. Quasispecies tropism and compartmentalization in gut and peripheral blood during early and chronic phases of HIV-1 infection: possible correlation with immune activation markers.
Rozera G; Abbate I; Vlassi C; Giombini E; Lionetti R; Selleri M; Zaccaro P; Bartolini B; Corpolongo A; D'Offizi G; Baiocchini A; Del Nonno F; Ippolito G; Capobianchi MR
Clin Microbiol Infect; 2014 Mar; 20(3):O157-66. PubMed ID: 24134524
[TBL] [Abstract][Full Text] [Related]
11. Role and evolution of viral tropism in patients with advanced HIV disease receiving intensified initial regimen in the ANRS 130 APOLLO trial.
Charpentier C; Joly V; Larrouy L; Fagard C; Visseaux B; de Verdière NC; Raffi F; Yeni P; Descamps D;
J Antimicrob Chemother; 2013 Mar; 68(3):690-6. PubMed ID: 23152480
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of R5 and X4 HIV variants in antiretroviral treatment experienced patients with virologic failure.
Ferrer P; Tello M; Montecinos L; Tordecilla R; Rodríguez C; Beltrán C; Guzmán MA; Ferrés M; Pérez CM; Afani A
J Clin Virol; 2014 Jul; 60(3):290-4. PubMed ID: 24793966
[TBL] [Abstract][Full Text] [Related]
13. Evolution of HIV-1 quasispecies and coreceptor use in cell reservoirs of patients on suppressive antiretroviral therapy.
Raymond S; Saliou A; Delobel P; Cazabat M; Pasquier C; Jeanne N; Sauné K; Massip P; Marchou B; Izopet J
J Antimicrob Chemother; 2014 Sep; 69(9):2527-30. PubMed ID: 24840625
[TBL] [Abstract][Full Text] [Related]
14. Factors associated with proviral DNA HIV-1 tropism in antiretroviral therapy-treated patients with fully suppressed plasma HIV viral load: implications for the clinical use of CCR5 antagonists.
Soulié C; Fourati S; Lambert-Niclot S; Malet I; Wirden M; Tubiana R; Valantin MA; Katlama C; Calvez V; Marcelin AG
J Antimicrob Chemother; 2010 Apr; 65(4):749-51. PubMed ID: 20150182
[TBL] [Abstract][Full Text] [Related]
15. Next generation sequencing reveals a high frequency of CXCR4 utilizing viruses in HIV-1 chronically infected drug experienced individuals in South Africa.
Matume ND; Tebit DM; Gray LR; Hammarskjold ML; Rekosh D; Bessong PO
J Clin Virol; 2018 Jun; 103():81-87. PubMed ID: 29661652
[TBL] [Abstract][Full Text] [Related]
16. Rescue of HIV-1 long-time archived X4 strains to escape maraviroc.
Baatz F; Struck D; Lemaire M; De Landtsheer S; Servais JY; Arendt V; Schmit JC; Perez Bercoff D
Antiviral Res; 2011 Dec; 92(3):488-92. PubMed ID: 22020304
[TBL] [Abstract][Full Text] [Related]
17. Role of pretreatment variables on plasma HIV RNA value at the sixth month of antiretroviral therapy including all first line drugs in HIV naïve patients: A path analysis approach.
Mengoli C; Basso M; Andreis S; Scaggiante R; Cruciani M; Ferretto R; Panese S; Manfrin V; Francisci D; Schiaroli E; Maffongelli G; Sarmati L; Andreoni M; Baldelli F; Palu' G; Parisi SG
PLoS One; 2019; 14(3):e0213160. PubMed ID: 30856186
[TBL] [Abstract][Full Text] [Related]
18. Structural equation modelling of viral tropism reveals its impact on achieving viral suppression within 6 months in treatment-naive HIV-1-infected patients after combination antiretroviral therapy.
Mengoli C; Andreis S; Scaggiante R; Cruciani M; Bosco O; Ferretto R; Leoni D; Maffongelli G; Basso M; Torti C; Sarmati L; Andreoni M; Palù G; Parisi SG
J Antimicrob Chemother; 2017 Jan; 72(1):220-226. PubMed ID: 27605599
[TBL] [Abstract][Full Text] [Related]
19. Comparison of two genotypic algorithms to determine HIV-1 tropism.
Soulié C; Derache A; Aimé C; Marcelin AG; Carcelain G; Simon A; Katlama C; Calvez V
HIV Med; 2008 Jan; 9(1):1-5. PubMed ID: 18199166
[TBL] [Abstract][Full Text] [Related]
20. Impact of triplicate testing on HIV genotypic tropism prediction in routine clinical practice.
Symons J; Vandekerckhove L; Paredes R; Verhofstede C; Bellido R; Demecheleer E; van Ham PM; van Lelyveld SF; Stam AJ; van Versendaal D; Nijhuis M; Wensing AM
Clin Microbiol Infect; 2012 Jun; 18(6):606-12. PubMed ID: 21906210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
